US FDA postpones verdict on Santarus ulcerative colitis drug
This article was originally published in Scrip
Executive Summary
Just days after Dutch regulators rejected its partner’s application in The Netherlands, Santarus got word from the US FDA it was postponing by three months its decision on whether to permit the firm to market Uceris (budesonide) for induction of remission of mild to moderate active ulcerative colitis.